Encochleated miriplatin - Matinas BioPharma
Alternative Names: LNC-miriplatinLatest Information Update: 22 Aug 2024
At a glance
- Originator Matinas BioPharma
- Class Antineoplastics; Cyclohexanes; Platinum complexes
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer